These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 10242491)

  • 1. Drug industry trying to change FDA's slow but sure policy.
    Demkovich LE
    Natl J (Wash); 1979 Jul; 11(29):1211-5. PubMed ID: 10242491
    [No Abstract]   [Full Text] [Related]  

  • 2. The FDA's restrictions against prescription drug advertising: more hindrance than help.
    Lorman AJ
    Healthspan; 1991 Nov; 8(10):3-7. PubMed ID: 10114942
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA's role in drug product recalls.
    Crawford SY
    Am J Hosp Pharm; 1991 Dec; 48(12):2595-6. PubMed ID: 1814194
    [No Abstract]   [Full Text] [Related]  

  • 4. The FDA's critical path initiative: a brief introduction.
    Coons SJ
    Clin Ther; 2009 Nov; 31(11):2572-3. PubMed ID: 20110002
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA's aseptic processing: proposed regulation.
    Barr DB
    J Parenter Sci Technol; 1993; 47(2):57-9. PubMed ID: 8515345
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA's regulation of prescription drug labeling: a role for implied preemption.
    Kendrick LC
    Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031
    [No Abstract]   [Full Text] [Related]  

  • 7. Comments on the proposed change in FDA's trade secrets policy.
    Hansen RW
    Am J Pharm Sci Support Public Health; 1977; 149(5):133-7. PubMed ID: 580696
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA's interferon-beta decision reignites orphan debate.
    Marshall A
    Nat Biotechnol; 1999 Apr; 17(4):324-5. PubMed ID: 10207871
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of FDA's new drug rule? Not much.
    Holthaus D
    Hospitals; 1987 Aug; 61(15):106. PubMed ID: 3596532
    [No Abstract]   [Full Text] [Related]  

  • 10. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
    Dorfman HL; Quinn VM; Brophy EA
    Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
    [No Abstract]   [Full Text] [Related]  

  • 11. Prescription for the Orphan Drug Act: the impact of the FDA's 1992 regulations and the latest congressional proposals for reform.
    Clissold DB
    Food Drug Law J; 1995; 50(1):125-47. PubMed ID: 10342989
    [No Abstract]   [Full Text] [Related]  

  • 12. Additions to FDA's drug use policy expected.
    J Am Vet Med Assoc; 1992 Aug; 201(4):533. PubMed ID: 1517124
    [No Abstract]   [Full Text] [Related]  

  • 13. Knowledge is power: legislative control of drug industry trade secrets.
    O'Reilly JT
    Spec Law Dig Health Care (Mon); 1987 May; 8(15):7-31. PubMed ID: 10281981
    [No Abstract]   [Full Text] [Related]  

  • 14. Medical costs and the drug industry.
    Schwartz H
    Wall St J Midwest Ed; 1980 Apr; 60(132):22. PubMed ID: 10245744
    [No Abstract]   [Full Text] [Related]  

  • 15. Keeping prescription drug advertising honest. FDA's watchful eye.
    Welsh JS
    Am Pharm; 1980 May; NS20(5):40-4. PubMed ID: 7395709
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA's treatment investigational new drug rule: one year later.
    Appler WD
    J Clin Psychopharmacol; 1988 Aug; 8(4):286-7. PubMed ID: 3209720
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of clinical guidelines in research: FDA's viewpoint.
    Freeman MM
    J Clin Pharmacol; 1977; 17(11-12):682-5. PubMed ID: 925187
    [No Abstract]   [Full Text] [Related]  

  • 18. The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):1-5. PubMed ID: 15757431
    [No Abstract]   [Full Text] [Related]  

  • 19. The drug approval process and the FDA.
    Schmidt AM
    Conn Med; 1975 Apr; 39(4):237-40. PubMed ID: 1149447
    [No Abstract]   [Full Text] [Related]  

  • 20. Second thoughts: do the FDA's responses to a fatal drug trial and the AIDS activist community's doubts about early access to drugs hint at a shift in basic FDA policy?
    Lovell MC
    Food Drug Law J; 1996; 51(2):273-94. PubMed ID: 11820202
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.